Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquinol-cytochrome c reductase core protein 2 (UQCRC2) is a critical component of mitochondrial Complex III (cytochrome b-c1 complex), a multisubunit enzyme complex of the respiratory chain. The protein is located on the inner mitochondrial membrane, where it stabilizes and is necessary for assembly of Complex III, which catalyzes electron transfer from ubiquinol to cytochrome c. UQCRC2 is part of the peptidase M16 family and is homologous to alpha-mitochondrial processing peptidases, though its established role is structural within the electron transport chain. Pathogenic variants in UQCRC2 cause mitochondrial complex III deficiency, leading to a spectrum of mitochondrial disorders, especially impacting organs with high energetic demand, such as brain, liver, and muscle[1][3][4][6].
N/A (not a current direct therapeutic target; general mechanisms would involve mitochondrial function modulation rather than direct modulation of UQCRC2)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquinol-cytochrome c reductase core protein 2 (UQCRC2).